In syngeneic mouse tumor models, intratumoral injection of JNJ-4412 was shown to result in increased levels of pro-inflammatory cytokines in tumor and plasma, increased frequencies of CD8+ T cells, loss of vascularization, increased apoptosis and significant regression of both injected and contralateral tumors. The gene discussed is CD8A; the disease is neoplasm.